ClearPoint Neuro, Inc. (CLPT) News

ClearPoint Neuro, Inc. (CLPT): $14.46

0.22 (+1.54%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CLPT News Items

CLPT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CLPT News From Around the Web

Below are the latest news stories about ClearPoint Neuro Inc that investors may wish to consider to help them evaluate CLPT as an investment opportunity.

ClearPoint Neuro: Underlying Growth Potential Concealed By COVID

This article is contributed by Jun Hao from our Superstocks Seekers team. [To receive real-time notifications of our latest updates/articles, click the "Follow" button on the left of your screen.] Overview ClearPoint Neuro (CLPT) is a neurological platform company that allows neurosurgeons to perform minimally invasive procedures for the most...

Superstocks Seekers on Seeking Alpha | January 14, 2022

Adirondack Trust Co Buys Vanguard Russell 2000 Index Fund, Ford Motor Co, Arco Platform, Sells ...

Saratoga Springs, NY, based Investment company Adirondack Trust Co (Current Portfolio) buys Vanguard Russell 2000 Index Fund, Ford Motor Co, Arco Platform, Kiniksa Pharmaceuticals, TransMedics Group Inc, sells Vanguard Russell 3000 Index Fund, Vanguard Total International Stock, AT&T Inc, Eli Lilly and Co, Vanguard FTSE Developed Markets ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Adirondack Trust Co.

Yahoo | January 13, 2022

ClearPoint Neuro to Participate at the H.C. Wainwright BIOCONNECT Virtual Conference

SOLANA BEACH, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will participate at the H.C. Wainwright BIOCONNECT Virtual Conference. A pre-recorded company presentation will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on January 10, 2022. About ClearPoint Neuro ClearPoint Neuro’s mission is to

Yahoo | January 5, 2022

Royce Value Trust, Inc. Buys Calix Inc, MaxCyte Inc, Dutch Bros Inc, Sells EQT Corp, ...

Investment company Royce Value Trust, Inc. (Current Portfolio) buys Calix Inc, MaxCyte Inc, Dutch Bros Inc, Eagle Materials Inc, Scientific Games Corp, sells EQT Corp, SmileDirectClub Inc, , Hilton Grand Vacations Inc, Kulicke & Soffa Industries Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Royce Value Trust, Inc..

Yahoo | December 17, 2021

ClearPoint Neuro (NASDAQ:CLPT) shareholders are still up 635% over 3 years despite pulling back 13% in the past week

It might be of some concern to shareholders to see the ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) share price down 20% in...

Yahoo | November 20, 2021

ClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the MoveAgain Brain-Computer Interface System

SOLANA BEACH, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Blackrock Neurotech for receiving Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its groundbreaking MoveAgain Brain Computer Interface (BCI) system. There are an estimated 5.35 million1 people in the United States who suffer from pa

Yahoo | November 17, 2021

ClearPoint Neuro Reports Third Quarter 2021 Results

Record Revenue Achieved; Company Reaffirms 2021 Revenue ForecastSOLANA BEACH, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2021. Third Quarter Highlights Reported record revenue of $4.6 million, a 30% year-over-year increase;Increased biologics and drug delivery revenue to $2.1 mi

Yahoo | November 9, 2021

ClearPoint Neuro Congratulates Neurona Therapeutics on IND Clearance for Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients

SOLANA BEACH, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Neurona Therapeutics on clearance by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application to initiate its first-in-human Phase 1/2 clinical trial evaluating the safety and efficacy of NRTX-1001 in patients with drug-resistant mes

Yahoo | November 8, 2021

ClearPoint Neuro to Present at the 2021 Stifel Virtual Healthcare Conference

SOLANA BEACH, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the 2021 Stifel Virtual Healthcare Conference on Tuesday, November 16, 2021 at 10:40 a.m. Eastern Time via invite only. Registration is available by contacting [email protected] An online archive of the broadcast will be available

Yahoo | November 4, 2021

Internationally Renowned Neurosurgeon and Accomplished Researcher Dr. Linda M. Liau Joins ClearPoint Neuro Board of Directors

SOLANA BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Linda M. Liau, MD, PhD, MBA, has been appointed to the Company’s Board of Directors effective immediately. Dr. Linda M. Liau is Professor and W. Eugene Stern Chair of the Department of Neurosurgery at the David Geffen School of Medicine at UCLA. She is the Co-Director o

Yahoo | November 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5497 seconds.